Sustainability and affordability of cancer drugs: a novel pricing model
Nature Reviews Clinical Oncology p. 1- 2
The affordability of newly approved anticancer agents is a challenge to many national health services and reimbursement systems. Therefore, we have developed an approach based upon the adoption of a novel model of price setting and herein provide examples of how it might be implemented. This model is intended to alter the balance between social and economic entrepreneurship.
|Nature Reviews Clinical Oncology
|Institute for Medical Technology Assessment (iMTA)
Uyl-de Groot, C., & Löwenberg, B. (2018). Sustainability and affordability of cancer drugs: a novel pricing model. Nature Reviews Clinical Oncology, 1–2. doi:10.1038/s41571-018-0027-x